US 9,808,450 B2
Solid forms comprising 3-(4-amino-1-OXO-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof
G. Patrick Stahly, West Lafayette, IN (US); David Jonaitis, Brookston, IN (US); Ho-Wah Hui, Basking Ridge, NJ (US); and Kevin J. Klopfer, Flemington, NJ (US)
Assigned to Celgene Corporation, Summit, NJ (US)
Appl. No. 14/780,495
Filed by CELGENE CORPORATION, Summit, NJ (US)
PCT Filed Mar. 25, 2014, PCT No. PCT/US2014/031689
§ 371(c)(1), (2) Date Sep. 25, 2015,
PCT Pub. No. WO2014/160686, PCT Pub. Date Oct. 2, 2014.
Claims priority of provisional application 61/805,425, filed on Mar. 26, 2013.
Prior Publication US 2016/0045483 A1, Feb. 18, 2016
Int. Cl. A61K 31/4015 (2006.01); C07D 401/04 (2006.01); A61K 31/454 (2006.01); C07D 209/46 (2006.01); A61K 45/06 (2006.01); A61K 31/573 (2006.01); A61K 9/20 (2006.01)
CPC A61K 31/454 (2013.01) [A61K 31/573 (2013.01); A61K 45/06 (2013.01); C07D 209/46 (2013.01); A61K 9/2018 (2013.01)] 38 Claims
 
1. A crystalline solid form comprising (a) 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, prodrug, or clathrate thereof; and (b) a coformer; wherein the coformer is benzoic acid, glycolic acid, hippuric acid, magnesium bromide, sodium lauryl sulfate, vanillic acid, or zinc chloride.